Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of liquiritin in preparing medicine for preventing and treating cerebral ischemia disease

A technology of cardiovascular and cerebrovascular diseases and liquiritin, which is applied in the field of medicine, can solve problems such as no relevant literature reports, and achieve the effects of no adverse reactions, prevention or improvement of heart and brain damage, and low cost

Inactive Publication Date: 2012-10-10
北京联合大学应用文理学院
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant literature report on the research on the prevention and treatment of cerebrovascular diseases by liquiritin (Rui Chunlan. Domestic research progress on the chemical constituents of licorice [J]. Chinese School Medicine, 2006, 20 (1): 105-106; Yang Yun, Bian Guangxing , Lv Qiujun. Protective and nutritional effects of liquiritin on primary hippocampal neurons[J]. Chinese Journal of Traditional Chinese Medicine, 2008, 33(8): 931-935; Zhao Zhiyu, Wang Weixing, Guo Hongzhu, et al. The impact of body weight and behavior [J]. Chinese Journal of Mental Health, 2006, 20 (12): 787-790; Liu Ruiting, Bian Guangxing, Zou Libo, etc. Neuroprotection of Liquiritin and its inhibitory effect on cholinesterase [J ]. Chinese Journal of New Drugs, 2008, 17 (7): 574-580; Wang Jianguo, Zhou Zhong, Liu Haifeng, etc. Active ingredients of licorice and its application in cosmetics [J]. Daily Chemical Industry, 2004, 34( (4): 249-251)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of liquiritin in preparing medicine for preventing and treating cerebral ischemia disease
  • Application of liquiritin in preparing medicine for preventing and treating cerebral ischemia disease
  • Application of liquiritin in preparing medicine for preventing and treating cerebral ischemia disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1 Liquiritin anti-simple cerebral ischemia effect

[0017] 1. Materials and Methods

[0018] 1.1 Experimental animals

[0019] Healthy adult male ICR mice, clean grade, weighing 25-30 g, were provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and acclimated to the environment in the SPF-level experimental animal room of the Applied Arts and Health Food Functional Testing Center of Beijing Union University for one week before the experiment.

[0020] 1.2 Reagents

[0021] Liquiritin standard substance: Tianjin Jianfeng Natural Products Company (purity ≥ 98%); Edaravone: Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.; red tetrazolium (2,3,5-triphenyltetrazolium, TTC): Sigma Company.

[0022] 1.3 Instruments

[0023] AR-2140 1 / 10,000 electronic balance: Mettler-Toledo Instrument Co., Ltd.; electric heating constant temperature water bath: Beijing Changfeng Instrument Co., Ltd.

[0024] 1.4 Preparation of permanent cerebral ischemi...

Embodiment 2

[0042] Embodiment 2 Liquiritin anti-cerebral ischemia-reperfusion effect

[0043] 1. Materials and Methods

[0044] 1.1 Experimental animals

[0045]Healthy adult male Wistar rats, clean grade, weighing 200-250 g, were provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and acclimatized to the environment for one week in the SPF-level experimental animal room of the Applied Arts, Science and Health Food Functional Testing Center of Beijing Union University before the experiment.

[0046] 1.2 Reagents

[0047] Standard Liquiritin: Tianjin Jianfeng Natural Products Company (purity ≥ 98%); Edaravone: Nanjing Simcere Dongyuan Pharmaceutical Co., Ltd.; MDA, MPO, SOD, Coomassie Brilliant Blue Kit: Nanjing Jiancheng Bioengineering Institute.

[0048] 1.3 Instruments

[0049] AR-2140 1 / 10000 electronic balance: Mettler-Toledo Instrument Co., Ltd.; electric heating constant temperature water bath: Beijing Changfeng Instrument Co., Ltd.; TGL 16M centrifuge: Hu...

Embodiment 3

[0063] Example 3 Liquiritin Anti-Cerebral Hypoxia Effect

[0064] 1. Materials and Methods

[0065] 1.1 Experimental animals

[0066] Healthy adult male ICR mice, clean grade, weighing 18-20 g, were provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and acclimated to the environment in the SPF laboratory animal room of the Applied Arts and Health Food Functional Testing Center of Beijing Union University for one week before the experiment.

[0067] 1.2 Reagents

[0068] Liquiritin standard product: Tianjin Jianfeng Natural Products Company (purity ≥ 98%); Edaravone: Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd.; sodium nitrite, Xi'an Chemical Reagent Factory.

[0069] 1.3 Instruments

[0070] AR-2140 1 / 10,000 electronic balance: Mettler-Toledo Instrument Co., Ltd.

[0071] 1.4 Acute cerebral ischemia and hypoxia experiment

[0072] 45 ICR mice were fasted for 12 hours and randomly divided into negative control (0.5% sodium carboxymethylcellu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, more specifically relates to the application of liquiritin in preparing medicine for preventing and treating cardiovascnlar and cerebrovascular disease, and in particular to the application of liquiritin in preparing medicine for preventing and treating cerebrovascular disease. A pharmacological test result of the invention proves that liquiritin has obvious functions of anti-cerebral ischemia, anti-cerebral anoxia, anti-cerebral thrombosis, and an obvious function of wide application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of liquiritin in the preparation of medicines for treating cardiovascular and cerebrovascular diseases, in particular to the application of liquiritin in the preparation of medicines for preventing and treating cerebral ischemic diseases. Background technique [0002] With the improvement of living standards and the quickening pace of life, cardiovascular and cerebrovascular diseases have become the No. 1 killer threatening the health and longevity of middle-aged and elderly people. Among them, cerebrovascular disease is one of the three major causes of death in human beings. It causes severe physical disabilities, speech barriers, and more seriously, vascular dementia, which brings various changes to individuals, families and society. . Therefore, finding ways to prevent and treat cerebrovascular diseases has become a hot spot in current research. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/00A61P9/10
Inventor 孙雅煊刘婷戴雪伶高兆兰张静王振华郑秋生姜招峰王志斌
Owner 北京联合大学应用文理学院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com